...
首页> 外文期刊>Natural product communications >Microbial Conversion of Tomato by a Plant Pathogenic Bacterium Pectobacterium atrosepticum: a Plant-Microbial Approach to Control Pathogenic Candida Species
【24h】

Microbial Conversion of Tomato by a Plant Pathogenic Bacterium Pectobacterium atrosepticum: a Plant-Microbial Approach to Control Pathogenic Candida Species

机译:番茄的植物病原性细菌杆菌介导的微生物转化:控制病原性念珠菌物种的植物-微生物方法。

获取原文
获取原文并翻译 | 示例
           

摘要

This study was carried out to produce bioconverted products by microbial fermentation of tomato using a plant pathogenic bacterium Pectobacterium atrosepticum and to evaluate their in vitro antimycotic effect against pathogenic Candida species. The bioconverted products (500 μg/disc) provoked promising antimycotic effects against pathogenic isolates of Candida species as shown by the diameters of zones of inhibition (9 ± 0.6 to 14 ± 0.4 mm), along with their respective minimum inhibitory and minimum fungicidal concentration values, which increased from 250 to 1000 and 250 to 2000 μg/mL, respectively. With the viable counts of the tested fungal pathogens, exposure of the bioconverted products revealed a remarkable antimycotic effect. In addition, the morphology of a clinical isolate of C. glabrata KBN06P00368, visualized by scanning electron microscopy, showed a severe detrimental effect produced by the bioconverted products at the minimum inhibitory concentration (250 μg/mL). The bioconverted products significantly inhibited the in vitro growth of all the tested clinical and pathogenic laboratory isolates of Candida species. This study confirmed the potent antimycotic efficacy of the bioconverted products of tomato, hence justifying the therapeutic uses of bioconverted products in pharmaceutical preparations as an alternative approach to support the antifungal activity of conventional antimycotics.
机译:进行了这项研究,以通过使用植物病原菌atrosepticum的番茄微生物发酵对番茄进行发酵来生产生物转化产品,并评估其对病原性念珠菌物种的体外抗真菌作用。生物转化产物(500μg/碟)对抑制念珠菌属的病原菌具有令人信服的抗真菌作用,如抑制区的直径(9±0.6至14±0.4 mm)以及它们各自的最小抑菌和最小杀真菌浓度值所示,分别从250微克/毫升和250微克/毫升增加至2000微克/毫升。随着测试真菌病原体的可行计数,生物转化产物的暴露显示出显着的抗真菌作用。此外,通过扫描电子显微镜观察的光滑念珠菌KBN06P00368临床分离株的形态显示,在最小抑制浓度(250μg/ mL)下,生物转化产物产生了严重的有害作用。经过生物转化的产品显着抑制了所有测试的念珠菌属临床和病原实验室分离株的体外生长。这项研究证实了番茄生物转化产品的强力抗霉菌功效,因此证明了生物转化产品在药物制剂中的治疗用途是支持常规抗真菌药抗真菌活性的替代方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号